Associated Papers
Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome.
Vagher J et al.
Jco Precision Oncology, 2025
40540701 (PubMed )
Supplement: DS2_PO-24-00860.xlsx › Supp_Table_1
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
The High Expression of p53 Is Predictive of Poor Survival Rather TP53 Mutation in Esophageal Squamous Cell Carcinoma.
Jin Y et al.
Journal of Oncology, 2023
Genomic Landscape of Head and Neck Squamous Cell Carcinoma Across Different Anatomic Sites in Chinese Population.
Ju Y et al.
Frontiers in Genetics, 2021
34194478 (PubMed )
Supplement: Data_Sheet_1.xlsx › Table_S6
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
29338072 (PubMed )
Supplement: CNCR-124-1358-s002.xlsx › Colon
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
Liu D et al.
Nature Communications, 2017
29259186 (PubMed )
Supplement: 41467_2017_2320_MOESM1_ESM.pdf
Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL et al.
Jama Oncology, 2017
Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
Miyoshi T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
27507618 (PubMed )
Supplement: 10780432ccr160355-sup-162074_1_supp_3593422_88n10b.xlsx › Supplementary_Table_8
Select a paper to view details